HOME >> MEDICINE >> NEWS
Transplant patients keep their new kidney longer with a CellCept-based drug combination

24 July 2006, Basel, Switzerland -- The largest ever comparative transplantation study, involving 1,645 kidney transplant patients, has revealed the best immunosuppressant drug regimen that will give patients a better chance of a normal life. CellCept (mycophenolate mofetil) plus low-dose tacrolimus, corticosteroids and IL-2 induction therapy was shown to be the top combination to prevent patients rejecting their new kidney whilst maximising the function and life of the new organ.

The results at 12 months showed significantly improved kidney function (15%, p<0.0001), up to a further 65% reduction in early rejection and up to 6% improvement in organ survival for patients receiving the CellCept plus low-dose tacrolimus combination. This could mean that, if all first time kidney recipients were to take this regimen, nearly 2,500* organs could be saved in the first year post transplant.

"The results of the SYMPHONY study are an exciting and long-awaited development for both patients and doctors," commented lead investigator, Professor Henrik Ekberg, from University Hospital, Malm, Sweden, following the study's presentation at the World Transplant Congress, Boston. "New immunosuppressant drugs have successfully reduced the rejection rates of the new organ. However, patients still face developing serious side effects from the life long use of some of these drugs. The focus is now to define the optimal balance of these combinations in order to prolong further the life of the patient and their transplanted organ. SYMPHONY now provides the answer for doctors that the best regimen for patients today is CellCept and low dose tacrolimus, steroids and induction therapy."

To prevent rejection of a new kidney by the patient's immune system, immunosuppressant combinations have traditionally contained high dose calcineurin inhibitor's (CNIs), which are now known to cause kidney damage due to toxic side effects. This damage can lead to loss of the n
'"/>

Contact: Helen swift
Helen.Swift@Ketchum.com
44-207-611-3637
Ketchum
24-Jul-2006


Page: 1 2

Related medicine news :

1. Transplanting human gut bugs into mice helps understanding of metabolic system
2. Transplanting organs from animals to humans -- what are the barriers?
3. Childrens surgeon to present results of new anti-rejection protocol at World Transplant Congress
4. Transplantation Report 2005
5. Transplantation of sperm stem cells restores fertility after chemotherapy
6. Transplanting kidneys which have stones poses little risk to organs viability
7. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
8. Comparison of obstetric outcomes between on-call and patients own obstetricians
9. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
10. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
11. Happier hospitals means healthier patients

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: